Masaharu Akao Selected Research

serofendic acid

1/2014	Serofendic acid protects against myocardial ischemia-reperfusion injury in rats.
1/2007	Serofendic acid, a substance extracted from fetal calf serum, as a novel drug for cardioprotection.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Masaharu Akao Research Topics

Disease

58	Atrial Fibrillation 09/2022 - 10/2008
42	Stroke (Strokes) 06/2022 - 01/2011
39	Hemorrhage 09/2022 - 07/2016
16	Coronary Artery Disease (Coronary Atherosclerosis) 09/2022 - 08/2018
16	Embolism (Embolus) 06/2022 - 01/2015
14	Heart Failure 09/2022 - 03/2004
11	Ischemic Stroke 01/2022 - 01/2015
10	Myocardial Infarction 01/2022 - 03/2003
9	Venous Thromboembolism 02/2022 - 07/2016
9	Neoplasms (Cancer) 01/2022 - 03/2004
6	Thrombosis (Thrombus) 11/2021 - 02/2009
5	Chronic Renal Insufficiency 01/2022 - 08/2014
5	Thromboembolism 01/2021 - 01/2019
4	Coronary Disease (Coronary Heart Disease) 09/2022 - 01/2019
4	Body Weight (Weight, Body) 01/2022 - 11/2020
3	Cardiac Arrhythmias (Arrythmia) 10/2022 - 01/2018
3	Unstable Angina 11/2021 - 10/2014
3	Hypertension (High Blood Pressure) 01/2021 - 12/2017
3	Cardiovascular Diseases (Cardiovascular Disease) 11/2018 - 10/2010
3	ST Elevation Myocardial Infarction 01/2018 - 10/2014
3	Atherosclerosis 11/2016 - 01/2011
3	Reperfusion Injury 01/2014 - 10/2006
2	Anemia 06/2022 - 11/2020
2	Thrombophilia 01/2022 - 04/2019
2	Death (Near-Death Experience) 01/2022 - 12/2018
2	Hypertrophy 10/2021 - 02/2006
2	Tachycardia (Tachyarrhythmias) 08/2021 - 01/2015
2	Weight Gain 11/2016 - 11/2015
2	Obesity 11/2016 - 01/2011
2	Infarction (Infarctions) 10/2014 - 01/2014
2	Myocardial Ischemia (Ischemic Heart Diseases) 01/2014 - 11/2003
2	Ischemia 01/2014 - 03/2003
2	Long QT Syndrome 10/2010 - 10/2009
2	Mitochondrial Diseases (Mitochondrial Disease) 10/2009 - 10/2003
2	Brugada Syndrome 10/2008 - 12/2005
1	Frailty 07/2022
1	Symptom Flare Up 01/2022
1	Thrombocytopenia (Thrombopenia) 01/2022
1	Intracranial Hemorrhages (Intracranial Hemorrhage) 01/2022
1	Stable Angina 10/2021
1	Atrial Flutter (Flutter, Atrial) 08/2021
1	Amyloidosis 02/2021
1	Cognitive Dysfunction 01/2021
1	Ventricular Fibrillation 01/2021
1	Shock 01/2021
1	Masked Hypertension 01/2021
1	Spasm (Spasms) 12/2020
1	Cardiac Sudden Death (Sudden Cardiac Arrest) 12/2020

Drug/Important Bio-Agent (IBA)

37	AnticoagulantsIBA 07/2022 - 04/2013
13	RivaroxabanIBA 09/2022 - 08/2017
12	apixabanIBA 06/2022 - 12/2016
11	Warfarin (Coumadin)FDA LinkGeneric 01/2022 - 04/2013
9	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 01/2022 - 08/2018
8	CreatinineIBA 09/2022 - 10/2014
6	edoxabanIBA 01/2022 - 12/2017
5	Vitamin K FDA Link 01/2019 - 01/2016
4	vinyltriethoxysilane (VTES)IBA 01/2020 - 01/2019
4	Pharmaceutical PreparationsIBA 12/2018 - 11/2003
4	oxidized low density lipoproteinIBA 11/2016 - 01/2011
3	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2022 - 01/2018
3	omega-Chloroacetophenone (Mace)IBA 01/2022 - 01/2011
3	Vascular Endothelial Growth Factor CIBA 01/2020 - 01/2011
2	Biomarkers (Surrogate Marker)IBA 01/2022 - 12/2020
2	fibrin fragment D (D-dimer)IBA 01/2022 - 05/2020
2	pro-brain natriuretic peptide (1-76)IBA 11/2021 - 01/2021
2	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 11/2021 - 02/2009
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 10/2021 - 01/2020
2	Hemoglobins (Hemoglobin)IBA 11/2020 - 01/2011
2	Anti-Arrhythmia AgentsIBA 12/2018 - 10/2009
2	CholesterolIBA 11/2018 - 01/2011
2	Syntex adjuvant formulationIBA 10/2018 - 12/2017
2	Lipoproteins (Lipoprotein)IBA 11/2016 - 11/2015
2	LDL Lipoproteins (beta Lipoproteins)IBA 11/2015 - 01/2012
2	serofendic acidIBA 01/2014 - 01/2007
2	Ion Channels (Ion Channel)IBA 10/2010 - 10/2009
2	Adenosine Triphosphate (ATP)IBA 10/2009 - 11/2003
2	Purinergic P2Y Receptor AntagonistsIBA 08/2009 - 02/2009
1	Heparin (Liquaemin)FDA LinkGeneric 02/2022
1	4-amino-4'-hydroxylaminodiphenylsulfone (HADS)IBA 01/2022
1	hydroxydione (P 234)IBA 01/2022
1	CreatineIBA 01/2022
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 10/2021
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 10/2021
1	pitavastatin (itavastatin)FDA Link 10/2021
1	Prealbumin (Transthyretin)IBA 02/2021
1	Factor Xa InhibitorsIBA 01/2021
1	Natriuretic PeptidesIBA 01/2021

Therapy/Procedure

44	Therapeutics 09/2022 - 10/2006
11	Percutaneous Coronary Intervention 09/2022 - 08/2009
5	Catheter Ablation 01/2022 - 12/2018
5	Stents 01/2020 - 02/2009
2	Drug Therapy (Chemotherapy) 10/2022 - 10/2019
2	Secondary Prevention 01/2020 - 04/2017
2	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 01/2019 - 08/2018
2	Intravenous Administration 01/2014 - 12/2005
1	Palliative Care (Palliative Therapy) 01/2022
1	Length of Stay 11/2021
1	Drug Tapering 07/2021
1	Electric Countershock (Cardioversion) 01/2021
1	Implantable Defibrillators (Implantable Cardioverter-Defibrillator) 12/2020